Cystic Fibrosis Drugs Market Analysis

Drug Class Segment Analysis

The CFTR modulators segment in the cystic fibrosis drugs market is anticipated to garner 45.6% of the share by 2037, owing to high drug efficacy. It is considered that Vertex’s Trikafta and Kalydeco are the only drugs suitable for curing the root cause of the diseases. The disease-modifying capabilities of the medicines are driving the adoption of the medicines. Also, the segment is witnessing high growth due to rising patient eligibility as the Trikafta label expansion now covers almost 90% of the patients suffering from CF. These medicines are considered because of superior clinical outcomes and pose fewer pulmonary exacerbations.

Route Segment Analysis

The oral delivery segment in the cystic fibrosis drugs market is projected to garner 65.5%, driven by ease of dosing and a high rate of patient adherence. People are shifting from the inhaled to oral modulators and have demonstrated superior efficacy in the oral form, lowering the reliance on the nebulized therapies. Additionally, more than 90% of the pediatric patients with CF prefer oral syrups in comparison with the inhaled routes. Oral therapies have lowered the hospitalization costs by conducting self-administration. For instance, NHS England has saved USD 50 million annually by switching 10.2% of the patients to oral modulators.

Our in-depth analysis of the global cystic fibrosis drugs market includes the following segments: